The company plans an Aug. 13 conference call to discuss second-quarter results, new pulmonary injury data for agenT-797 and the launch of a named-patient program.
MiNK Therapeutics said it will report financial results for the quarter ended June 30, 2026, before the market opens on Aug. 13 and will host a conference call and webcast at 8:30 a.m. ET. The company said the update will focus on the clinical advancement of agenT-797, its off-the-shelf allogeneic invariant natural killer T cell therapy, in acute lung injury. Management also plans to share new clinical data on agenT-797 in patients with pulmonary injury and provide details on the launch of MiNK’s named-patient program. MiNK describes itself as a clinical-stage biopharmaceutical company developing allogeneic iNKT cell therapies and precision immune modulators for cancer and immune disorders.